|
|
- The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
|
|
|
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
|
|
|
- Technically, the stock approaches a strong medium-term resistance at JPY 1767.
- For the past seven days, analysts have been lowering their EPS expectations for the company.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
|
|
|
|
|
| Sector Pharmaceuticals - NEC |
|
| | 1st jan. | Capitalisation (M$) | Investor Rating |
 |
 | ASTELLAS PHARMA INC. | 5.71% | 30 155 | |
| |
|
|
|
| Sales 2021 |
1 272 B
12 263 M
12 263 M
|
| Net income 2021 |
181 B
1 746 M
1 746 M
|
| Net cash 2021 |
440 B
4 242 M
4 242 M
|
| P/E ratio 2021 |
17,0x |
| Yield 2021 |
2,50% |
|
| Capitalization |
3 130 B
30 155 M
30 178 M
|
| EV / Sales 2021 |
2,11x |
| EV / Sales 2022 |
1,93x |
| Nbr of Employees |
15 883 |
| Free-Float |
99,2% |
|
Upcoming event on ASTELLAS PHARMA INC.
Notations Surperformance© Fundamental ratings
|
Overall rating |
| Trading Rating |
|
| Investor Rating |
|
| Growth (Revenue) |
|
| Valuation |
|
| Finances |
|
| Profitability |
|
| Earnings quality |
|
| Business Predictability |
|
| P/E ratio |
|
| Potential |
|
| Yield |
- |
| Consensus |
|
| 7 days EPS revision |
|
| 4 months EPS revision |
|
| 1 year EPS revision |
|
| 4 months Revenue revision |
|
| 1 year Revenue revision |
|
Technical ratings
| Short Term Timing |
|
| Middle Term Timing |
|
| Long Term Timing |
|
| RSI |
|
| Bollinger Spread |
|
| Unusual Volumes |
|
|
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
